RDNT
RadNet, Inc.71.22
-1.35-1.87%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
TechLive boosts volumes, EBCD payer wins
Q&A unpacked TechLive's rollout, slashing exam closures 42% across 83 New York centers to drive same-center MRI gains, while AI dynamic scheduling overbooks via no-show predictions. EBCD notched more capitated coverage like Desert Oasis, fueling 45%+ adoption and commercial payer pressure. Robust health system JV interest surfaced, labor stabilizing at an inflection point via remote staffing. Medicaid exposure tiny at 2.5%. Management stayed bullish on AI efficiencies; watch Investor Day for the three-year roadmap.
Key Stats
Market Cap
5.50BP/E (TTM)
-Basic EPS (TTM)
-0.16Dividend Yield
0%Recent Filings
8-K
Shelf registration filed
8-K
Record Q3 revenue, raised guidance
RadNet posted record Q3 revenue of $522.9M, up 13.4% year-over-year, with Adjusted EBITDA climbing 15.2% to $84.9M and margins edging up 26 bps to 16.2%. Advanced imaging volumes surged 13.0% aggregate, 9.9% same-center, fueled by capacity builds and acquisitions. Cash hit $804.7M; leverage at 1.0x. Strong trends prompt raised 2025 guidance for Imaging Center revenue to $1.90-1.93B and EBITDA to $276-284M.
10-Q
Q3 FY2025 results
RadNet drove Q3 revenue to $522.9M, up 13.4% y/y from $461.1M, with service fees climbing 14.9% y/y on 9.6% same-center growth fueled by advanced imaging. Operating income dipped to $27.4M from $33.9M y/y, squeezed by lease abandonment charges and higher staffing costs, yet margins held amid acquisitions like iCAD (closed July 2025 for $110.7M stock) boosting Digital Health. Cash swelled to $804.7M with $214.7M operating cash flow (FCF not disclosed in the 10-Q); debt steady at $1.1B with $325M revolver availability. EPS rose to $0.07 from $0.04, confirmed vs. 77.4M diluted shares. Acquisitions accelerate AI capabilities. Reimbursement shifts remain a headwind.
8-K
Prospectus for stock resale filed
RadNet filed a prospectus supplement on October 21, 2025, registering up to 59,444 shares of common stock for resale by selling stockholders under its shelf registration. This routine filing, backed by counsel opinion from Reed Smith LLP, enables potential liquidity for those holders without direct company proceeds. No new capital raises involved. Selling stockholders gain resale flexibility.
10-Q
Q2 FY2025 results
RadNet's Q2 revenue climbed 8.4% year-over-year to $498.2M, fueled by 4.4% same-center growth and acquisitions, while operating income dipped 11.3% to $30.9M amid higher medical supplies and staffing costs. Gross margin held steady at 13.8%, but net income attributable to common stockholders swung to $14.5M profit from a $3.0M loss, thanks to lower interest expense of $17.2M (down 34.1% y/y) after refinancing. Acquisitions added $32.0M in goodwill, including See-Mode Technologies for $28.7M (cash/holdback/contingent mix), bolstering AI capabilities. Cash swelled to $833.2M with $161.8M operating cash flow; total debt stands at $1.1B under term loans maturing 2027-2031, with $324.6M revolver availability. Free cash flow hit $60.1M (derived). Yet reimbursement pressures from payors loom large.
IPO
Website
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
DGX
Quest Diagnostics Incorporated
178.66-5.45
FONR
Fonar Corporation
14.35-0.40
GEHC
GE HealthCare Technologies Inc.
82.25-2.20
GH
Guardant Health, Inc.
100.00-2.67
NEO
NeoGenomics, Inc.
11.67-0.25
NNOX
NANO-X IMAGING LTD
3.21-0.03
ONMD
OneMedNet Corp
1.41+0.17
QTIH
QT Imaging Holdings, Inc.
6.10-0.02
RADX
Radiopharm Theranostics Limited
5.99-4.64